Your browser doesn't support javascript.
loading
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines.
Saunders, Deborah P; Rouleau, Tanya; Cheng, Karis; Yarom, Noam; Kandwal, Abhishek; Joy, Jamie; Bektas Kayhan, Kivanc; van de Wetering, Marianne; Brito-Dellan, Norman; Kataoka, Tomoko; Chiang, Karen; Ranna, Vinisha; Vaddi, Anusha; Epstein, Joel; Lalla, Rajesh V; Bossi, Paolo; Elad, Sharon.
Afiliación
  • Saunders DP; Dental Oncology Program, Health Sciences North, North East Cancer Center, Northern Ontario School of Medicine, 41 Ramsey Lake Road, Sudbury, Ontario, P3E 5J1, Canada. dsaunders@hsnsudbury.ca.
  • Rouleau T; Dental Oncology Program, Health Sciences North, North East Cancer Center, Northern Ontario School of Medicine, 41 Ramsey Lake Road, Sudbury, Ontario, P3E 5J1, Canada.
  • Cheng K; Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Yarom N; Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel and School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Kandwal A; Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himayalan University, Dehradun, Uttarakhand, India.
  • Joy J; Clinical Pharmacy, Cancer Treatment Centers of America, Boca Raton, FL, USA.
  • Bektas Kayhan K; Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Istanbul University, Istanbul, Turkey.
  • van de Wetering M; Paediatric Oncology Department, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands.
  • Brito-Dellan N; Division of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kataoka T; Multi-institutional Clinical Trials Section, Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
  • Chiang K; Pharmacy Department, St Vincent's Hospital Melbourne, Electronic Medical Records Department, Melbourne Health, Jane Bell House, Melbourne, Victoria, Australia.
  • Ranna V; Department of Oral and Maxillofacial Surgery, The Mount Sinai Hospital, New York, NY, USA.
  • Vaddi A; Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.
  • Epstein J; Cedars-Sinai Health System, Los Angeles CA and City of Hope National Medical Center, Duarte, CA, USA.
  • Lalla RV; Section of Oral Medicine, University of Connecticut School of Dental Medicine, Farmington, CT, USA.
  • Bossi P; Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.
  • Elad S; Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.
Support Care Cancer ; 28(5): 2473-2484, 2020 May.
Article en En | MEDLINE | ID: mdl-32052137
PURPOSE: To update the clinical practice guidelines for the use of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and/or treatment of oral mucositis (OM). METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible. RESULTS: A total of 9 new papers were identified within the scope of this section, adding to the 62 papers reviewed in this section previously. A new Suggestion was made for topical 0.2% morphine for the treatment of OM-associated pain in head and neck (H&N) cancer patients treated with RT-CT (modification of previous guideline). A previous Recommendation against the use of sucralfate-combined systemic and topical formulation in the prevention of OM in solid cancer treatment with CT was changed from Recommendation Against to No Guideline Possible. Suggestion for doxepin and fentanyl for the treatment of mucositis-associated pain in H&N cancer patients was changed to No Guideline Possible. CONCLUSIONS: Of the agents studied for the management of OM in this paper, the evidence supports a Suggestion in favor of topical morphine 0.2% in H&N cancer patients treated with RT-CT for the treatment of OM-associated pain.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estomatitis / Mucositis / Analgésicos / Anestésicos / Antiinfecciosos Tipo de estudio: Guideline / Prognostic_studies / Systematic_reviews Límite: Adult / Humans / Male Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estomatitis / Mucositis / Analgésicos / Anestésicos / Antiinfecciosos Tipo de estudio: Guideline / Prognostic_studies / Systematic_reviews Límite: Adult / Humans / Male Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Alemania